Tafalgie Therapeutics came into being in October 2020.
This company brings together researchers and entrepreneurs with the shared aim of valorizing more than 10 years of fundamental research conducted by Dr. Aziz Moqrich and his team.
This work has been the subject of numerous publications and an international patent has been filed (by the SATT on behalf of the CNRS and AMU) concerning the use of a new protein as a potential analgesic for treating inflammatory and neuropathic pain.
Discovery of the type C low-threshold mechanoreceptor neuron class (C-LTMR) by Yngve Zotterman
Identification of the TAFA4 protein as a specific molecular marker of C-LTMR sensory neurons
Elucidation, by the team of Aziz Moqrich, of the role of the TAFA4 protein in pain gate control
Filing of a first patent linked to TAFA4 by Aziz Moqrich
Filing of two new product patents in December 2021 and May 2022 (for polypeptide derived from TAFA4) by Tafalgie Therapeutics and the CNRS
Creation of the Team ‘Chronic Pain’.
Molecular and cellular mechanisms” team by Dr. Aziz Moqrich from the IBDM, and Dr. Stephane Gaillard, who joined this new team
Sublicense exploitation agreement
// Satt Sud-Est (SEE).
Creation of the society Tafalgie Therapeutics.
Completion of the Tafalgie Therapeutics founders by the arrival of Laurent Labatut and the establishment of a support team
The company begins operating, with the performance of preclinical studies…
R&D activities, regulatory activities, the establishment of a scientific advisory board and efforts to obtain financial support
Alain Eschalier (MD, PhD, PharmD) is Professor Emeritus of Medical Pharmacology at the University of Clermont, Auvergne, France and is board-certified in pharmacology, psychiatry and human biology.
Dr. Clifford J. Woolf was born in South Africa, where he earned his MB, BCh, and PhD degrees. He then moved to London and became Professor of Neurobiology at University College London. In 1997, he was recruited by the Massachusetts General Hospital and Harvard Medical School to serve as the Richard J. Kitz Professor of Anesthesiology Research.
His research focuses on the roles of the functional, chemical and structural plasticity of neurons in both the normal adaptive functions of nervous systems and in the maladaptive changes contributing to neurological diseases. He focuses, in particular, on pain, regeneration and neurodegeneration and on the exploitation of stem cell-derived neurons for disease modeling and drug screening.
Jean-Louis Kraus is Professor Emeritus at the University of Aix Marseille, France and was formerly Professor at McGill University in Montreal, Canada.
Prof. Kraus’s considerable experience and commercial success have enabled him to develop extensive networks during the course of his career.
• Prof. Levine’s research focuses on pain and analgesia, including, in particular, the mechanism by which the placebo effect can relieve pain. In 1978, he published an influential study showing that placebo analgesia could be blocked by the opioid antagonist naloxone.
His research has led to the identification of new ion channels and receptors activated by temperature, mechanical force, and increases in cell volume. His laboratory has shown that these ion channels play crucial roles in sensing temperature, touch, and pain, in proprioception, and in regulating vascular tone.
Patapoutian was born in Lebanon in 1967 and attended the American University of Beirut for one year before emigrating to The United States in 1986. He became a US citizen, graduating from UCLA in 1990 and obtaining a PhD from Caltech in 996, for his work in the laboratory of Dr. Barbara Wold.
Following his postdoctoral work with Dr. Lou Reichardt at UCSF, he joined the Scripps Research Institute faculty in 2000, and is currently Professor in the Department of Neuroscience. He also held a position at the Genomics Institute of The Novartis Research Foundation from 2000-2014.
Patapoutian was awarded the Young Investigator Award from the Society for Neuroscience in 2006 and was named an Investigator of the Howard Hughes Medical Institute in 2014.
He is a fellow of the American Association for the Advancement of Science (2016), a member of the National Academy of Sciences (2017) and a member of the American Academy of Arts and Sciences (2020). He received the 2017 Alden Spencer Award from Columbia University (together with David Ginty), the 2019 Rosenstiel Award for Distinguished Work in Basic Medical Research (with David Julius), the 2020 Kavli Prize in Neuroscience (with David Julius), the 2021 BBVA Foundation Frontiers of Knowledge Award (shared with David Julius), and the 2021 Nobel Prize in Physiology or Medicine (with David Julius).
2021 : Nobel Prize in Physiology or Medicine (with David Julius)